Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing.

Dheda K, Lenders L, Srivastava S, Magombedze G, Wainwright H, Raj P, Bush SJ, Pollara G, Steyn R, Davids M, Pooran A, Pennel T, Linegar A, McNerney R, Moodley L, Pasipanodya JG, Turner CT, Noursadeghi M, Warren RM, Wakeland E, Gumbo T.

Am J Respir Crit Care Med. 2019 Jan 29. doi: 10.1164/rccm.201807-1361OC. [Epub ahead of print]

PMID:
30694692
2.

Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Martin KR, Athale S, van Zyl J, Antiabong J, Koeuth T, Lee PS, Dheda K, Gumbo T.

J Infect Dis. 2018 Dec 28. doi: 10.1093/infdis/jiy587. [Epub ahead of print]

PMID:
30597040
3.

Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S327-S335. doi: 10.1093/cid/ciy625.

PMID:
30496467
4.

Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!

Srivastava S, Deshpande D, Magombedze G, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S359-S364. doi: 10.1093/cid/ciy627.

PMID:
30496465
5.

Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.

Magombedze G, Pasipanodya JG, Srivastava S, Deshpande D, Visser ME, Chigutsa E, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S349-S358. doi: 10.1093/cid/ciy623.

PMID:
30496464
6.

The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.

Srivastava S, Deshpande D, Nuermberger E, Lee PS, Cirrincione K, Dheda K, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S336-S341. doi: 10.1093/cid/ciy626.

PMID:
30496463
7.

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi: 10.1093/cid/ciy611.

PMID:
30496461
8.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

PMID:
30496460
9.

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Bendet P, Koeuth T, Bhavnani SM, Ambrose PG, Smythe W, McIlleron H, Thwaites G, Gumusboga M, Van Deun A, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S274-S283. doi: 10.1093/cid/ciy618.

PMID:
30496459
10.

Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.

Pasipanodya JG, Smythe W, Merle CS, Olliaro PL, Deshpande D, Magombedze G, McIlleron H, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S284-S292. doi: 10.1093/cid/ciy610.

PMID:
30496458
11.

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T, Lee PS, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S317-S326. doi: 10.1093/cid/ciy609.

PMID:
30496457
12.

Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.

Deshpande D, Srivastava S, Nuermberger E, Koeuth T, Martin KR, Cirrincione KN, Lee PS, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S342-S348. doi: 10.1093/cid/ciy612.

PMID:
30496456
13.

Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.

Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S267-S273. doi: 10.1093/cid/ciy608.

PMID:
30496455
14.

Mapping spatial locational trends of informal economic enterprises using mobile geographic information data in the city of in Harare, Zimbabwe.

Gumbo T, Geyer M, Moyo I, Moyo T.

Data Brief. 2018 Sep 18;20:1692-1699. doi: 10.1016/j.dib.2018.09.037. eCollection 2018 Oct.

15.

Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis.

Court RG, Wiesner L, Chirehwa MT, Stewart A, de Vries N, Harding J, Gumbo T, McIlleron H, Maartens G.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):926-930. doi: 10.5588/ijtld.18.0091.

16.

Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis.

Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E, Ashcraft P, Bottiglieri T, Wainwright H, Pennel T, Linegar A, Moodley L, Pooran A, Pasipanodya JG, Sirgel FA, van Helden PD, Wakeland E, Warren RM, Gumbo T.

Am J Respir Crit Care Med. 2018 Nov 1;198(9):1208-1219. doi: 10.1164/rccm.201711-2333OC.

PMID:
29877726
17.

Clofazimine for the Treatment of Mycobacterium kansasii.

Srivastava S, Gumbo T.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00248-18. doi: 10.1128/AAC.00248-18. Print 2018 Aug.

18.

Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.

Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.

PMID:
29697766
19.

Pan-tuberculosis regimens: an argument against.

Dheda K, Gumbo T, Lange C, Horsburgh CR Jr, Furin J.

Lancet Respir Med. 2018 Apr;6(4):240-242. doi: 10.1016/S2213-2600(18)30097-3. No abstract available.

PMID:
29595502
20.

Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?

Pasipanodya JG, Gumbo T.

Clin Infect Dis. 2018 Aug 16;67(5):717-718. doi: 10.1093/cid/ciy184. No abstract available.

PMID:
29514180
21.

Reply to Zimenkov, "Mutation in luxR Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance".

Srivastava S, Gumbo T.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02296-17. doi: 10.1128/AAC.02296-17. Print 2018 Mar. No abstract available.

22.

Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.

Court R, Wiesner L, Stewart A, de Vries N, Harding J, Maartens G, Gumbo T, McIlleron H.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):30-33. doi: 10.5588/ijtld.17.0475.

PMID:
29297422
23.

Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment.

Zentner I, Modongo C, Zetola NM, Pasipanodya JG, Srivastava S, Heysell SK, Mpagama S, Schlect HP, Gumbo T, Bisson GP, Vinnard C.

Int J Infect Dis. 2018 Mar;68:18-23. doi: 10.1016/j.ijid.2017.12.017. Epub 2017 Dec 15.

24.

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

Deshpande D, Srivastava S, Bendet P, Martin KR, Cirrincione KN, Lee PS, Pasipanodya JG, Dheda K, Gumbo T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02232-17. doi: 10.1128/AAC.02232-17. Print 2018 Feb.

25.

Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.

Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

PLoS One. 2017 Nov 2;12(11):e0187624. doi: 10.1371/journal.pone.0187624. eCollection 2017.

26.

Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease.

Pasipanodya JG, Ogbonna D, Deshpande D, Srivastava S, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i3-i19. doi: 10.1093/jac/dkx311. Review.

PMID:
28922813
27.

A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting.

Deshpande D, Srivastava S, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i54-i60. doi: 10.1093/jac/dkx309.

PMID:
28922811
28.

A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease.

Srivastava S, Deshpande D, Sherman CM, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i43-i47. doi: 10.1093/jac/dkx308.

PMID:
28922810
29.

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.

Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i48-i53. doi: 10.1093/jac/dkx307.

PMID:
28922809
30.

The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent.

Deshpande D, Srivastava S, Chapagain ML, Lee PS, Cirrincione KN, Pasipanodya JG, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i36-i42. doi: 10.1093/jac/dkx306.

PMID:
28922808
31.

Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.

Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i30-i35. doi: 10.1093/jac/dkx305.

PMID:
28922807
32.

Linezolid as treatment for pulmonary Mycobacterium avium disease.

Deshpande D, Srivastava S, Pasipanodya JG, Gumbo T.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i24-i29. doi: 10.1093/jac/dkx304.

PMID:
28922806
33.
34.

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

Deshpande D, Srivastava S, Chapagain M, Magombedze G, Martin KR, Cirrincione KN, Lee PS, Koeuth T, Dheda K, Gumbo T.

Sci Adv. 2017 Aug 30;3(8):e1701102. doi: 10.1126/sciadv.1701102. eCollection 2017 Aug.

35.

Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science.

Alffenaar JC, Migliori GB, Gumbo T.

Lancet Infect Dis. 2017 Sep;17(9):898. doi: 10.1016/S1473-3099(17)30449-8. No abstract available.

PMID:
28845791
36.

pH Conditions under Which Pyrazinamide Works in Humans.

Srivastava S, Pasipanodya JG, Gumbo T.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00854-17. doi: 10.1128/AAC.00854-17. Print 2017 Sep. No abstract available.

37.

Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.

Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01206-17. doi: 10.1128/AAC.01206-17. Print 2017 Nov.

38.

Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.

van Rijn SP, Srivastava S, Wessels MA, van Soolingen D, Alffenaar JC, Gumbo T.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e02039-16. doi: 10.1128/AAC.02039-16. Print 2017 Sep.

39.

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.

Srivastava S, Magombedze G, Koeuth T, Sherman C, Pasipanodya JG, Raj P, Wakeland E, Deshpande D, Gumbo T.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00751-17. doi: 10.1128/AAC.00751-17. Print 2017 Aug.

40.

Supervised Machine-Learning Reveals That Old and Obese People Achieve Low Dapsone Concentrations.

Hall RG 2nd, Pasipanodya JG, Swancutt MA, Meek C, Leff R, Gumbo T.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):552-559. doi: 10.1002/psp4.12208. Epub 2017 Jul 13.

41.

Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.

Vinnard C, Ravimohan S, Tamuhla N, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

J Antimicrob Chemother. 2017 Jul 1;72(7):2020-2027. doi: 10.1093/jac/dkx111.

42.

Reply to Raoult.

Seddon JA, Makhene MK, Gumbo T.

Clin Infect Dis. 2017 Apr 1;64(7):984. doi: 10.1093/cid/cix038. No abstract available.

43.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
44.

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.

Rockwood N, Pasipanodya JG, Denti P, Sirgel F, Lesosky M, Gumbo T, Meintjes G, McIlleron H, Wilkinson RJ.

Clin Infect Dis. 2017 May 15;64(10):1350-1359. doi: 10.1093/cid/cix158.

45.

Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.

Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, Fennelly KP, Te Riele J, Mastrapa B, Streicher EM, Dolby T, Abdallah AM, Ben-Rached F, Simpson J, Smith L, Gumbo T, van Helden P, Sirgel FA, McNerney R, Theron G, Pain A, Clark TG, Warren RM.

Lancet Respir Med. 2017 Apr;5(4):269-281. doi: 10.1016/S2213-2600(16)30433-7. Epub 2017 Jan 19.

PMID:
28109869
46.

Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.

Hall RG Nd, Pasipanodya JG, Meek C, Leff RD, Swancutt M, Gumbo T.

CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):674-681. doi: 10.1002/psp4.12146. Epub 2016 Nov 21.

47.

Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Vinnard C, Ravimohan S, Tamuhla N, Ivaturi V, Pasipanodya J, Srivastava S, Modongo C, Zetola NM, Weissman D, Gumbo T, Bisson GP.

Br J Clin Pharmacol. 2017 Apr;83(4):801-811. doi: 10.1111/bcp.13172. Epub 2016 Dec 9.

48.

Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.

Gumbo T, Makhene MK, Seddon JA.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S110-S115. Review.

49.

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.

Srivastava S, Deshpande D, Pasipanodya J, Nuermberger E, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S102-S109.

50.

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.

Deshpande D, Srivastava S, Nuermberger E, Pasipanodya JG, Swaminathan S, Gumbo T.

Clin Infect Dis. 2016 Nov 1;63(suppl 3):S95-S101.

Supplemental Content

Support Center